August 24, 2023 10:46 AM EDTUpdated 11:19 AM
News Briefing

Ake­bia ex­pects to file vadadu­s­tat again to FDA by end of Q3; So­ci­etal CD­MO seeks to se­cure 8M+ in lat­est raise

Tyler Patchen

News Reporter

Paul Schloesser

Associate Editor

Ake­bia now ex­pects to re­file its chron­ic kid­ney dis­ease treat­ment vadadu­s­tat by the end of Sep­tem­ber.

The biotech said Thurs­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times